A Prospective, Single-arm Phase II Study of Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
Status: Recruiting
Location: See location...
Intervention Type: Drug, Radiation
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Histologically confirmed type AB or B1-3 thymoma.
• Measurable Disease: Patients must have measurable disease as defined by RECIST (Response Evaluation Criteria in Solid Tumors).
• Unresectable or recurrent thymoma, with the tumor confined to the chest and neck area.
• Between the ages of 18 and 70 years, regardless of sex.
• Eastern Cooperative Oncology Group performance status of 0 or 1.
• No prior chest radiation.
• Adequate organ Functions.
• Written informed consent obtained.
Locations
Other Locations
China
Sun yat-sen University Cancer Center
RECRUITING
Guanzhou
Time Frame
Start Date: 2024-11-20
Estimated Completion Date: 2028-11-19
Participants
Target number of participants: 45
Treatments
Experimental: Study arm
Methylprednisolone combined with concurrent chemoradiotherapy
Related Therapeutic Areas
Sponsors
Leads: Sun Yat-sen University